SPDR S&P Biotech ETF Rating $156.61 +1.58 (+1.02%) Closing price 09/28/2026 04:10 PM EasternExtended Trading$156.76 +0.15 (+0.09%) As of 09/28/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest SPDR S&P Biotech ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.67Holdings in XBI have an aggregate rating of Moderate Buy based on 493 analyst ratings issued in the past year covering 25 companies (37.2% of the portfolio).XBI Aggregate Price Target$156.61High Prediction$156.61Average Prediction$156.61Low Prediction$156.61Holdings in XBI have an aggregate price target of $156.61 and a range of $156.61 to $156.61 covering 25 companies (37.2% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy21 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XBI Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings1.95%MRNAModerna$197.28-0.8%Hold$76.72 -61.1%241.9702 of 5 stars1.84%TWSTTwist Bioscience$179.60-1.8%Moderate Buy$103.00 -42.7%121.4078 of 5 stars1.72%NTRANatera$411.77-0.2%Moderate Buy$336.07 -18.4%232.0814 of 5 stars1.57%BIIBBiogen$228.69+0.5%Moderate Buy$230.14 0.6%322.2792 of 5 stars1.54%ABBVAbbVie$266.39+0.8%Moderate Buy$272.66 2.4%313.8078 of 5 starsTrending News1.52%HALOHalozyme Therapeutics$112.89-0.9%Moderate Buy$91.20 -19.2%132.8153 of 5 stars1.51%AMGNAmgen$418.13+0.8%Hold$385.25 -7.9%303.4203 of 5 starsAnalyst Forecast1.51%GILDGilead Sciences$152.21+0.8%Moderate Buy$158.78 4.3%293.8202 of 5 stars1.49%CRSPCRISPR Therapeutics$54.09-0.3%Moderate Buy$67.94 25.6%172.776 of 5 starsAnalyst Forecast1.49%TGTXTG Therapeutics$56.19-2.2%Hold$63.00 12.1%93.2719 of 5 stars1.47%SYRESpyre Therapeutics$85.79+0.1%Moderate Buy$109.69 27.9%152.4779 of 5 stars1.44%REGNRegeneron Pharmaceuticals$752.25-4.5%Moderate Buy$802.18 6.6%243.9512 of 5 stars1.44%VRTXVertex Pharmaceuticals$527.67+0.3%Moderate Buy$575.13 9.0%233.4861 of 5 starsAnalyst Forecast1.44%INCYIncyte$124.82+0.8%Moderate Buy$124.80 0.0%253.0218 of 5 starsTrending NewsAnalyst Forecast1.43%KRYSKrystal Biotech$337.08-2.5%Moderate Buy$377.20 11.9%134.2037 of 5 stars1.43%ORKAOruka Therapeutics$84.19-0.3%Moderate Buy$128.91 53.1%112.9135 of 5 stars1.41%EXELExelixis$58.37+0.4%Hold$50.29 -13.9%203.1799 of 5 stars1.41%VKTXViking Therapeutics$33.03-7.1%Moderate Buy$99.67 201.7%122.9865 of 5 starsAnalyst Upgrade1.40%UTHRUnited Therapeutics$485.54+2.1%Moderate Buy$621.00 27.9%144.3696 of 5 starsTrending NewsInsider Trade1.40%BMRNBioMarin Pharmaceutical$59.46-1.3%Moderate Buy$89.17 50.0%234.174 of 5 stars1.39%ALNYAlnylam Pharmaceuticals$255.36-0.2%Moderate Buy$367.20 43.8%233.6767 of 5 stars1.38%PTGXProtagonist Therapeutics$142.44+0.4%Moderate Buy$147.13 3.3%181.6161 of 5 starsPositive News1.36%MDGLMadrigal Pharmaceuticals$517.04+0.1%Moderate Buy$710.20 37.4%183.1725 of 5 stars1.35%ALKSAlkermes$40.15-1.7%Moderate Buy$54.47 35.7%193.0272 of 5 stars1.34%PTCTPTC Therapeutics$65.95+5.2%Moderate Buy$99.08 50.2%153.5859 of 5 stars This page (NYSEARCA:XBI) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
